NEWS

November 4, 2014 - Aria Neurosciences announced today that it received an Entrepreneur Innovation Award (EIA) from CTNext after presenting the Company's technology on October 23, 2014.  The award provides $10,000 for innovative project ideas that help propel startups to the next level.  Click here to download the official press release.

 

June 9, 2014:  Aria Neurosciences, Inc. announced today that a team led by Martin Sadowski, MD, PhD, at NYU Langone Medical Center, published preclinical results for its compound ARN-2966 (2-PMAP). The work appeared online in Annals of Neurology on June 03 (Asuni AA et al. Ann Neurol (2014) DOI:10.1002/ana.24149).

 

The research revealed that 2-PMAP reduced the production of amyloid beta's mother protein, known as amyloid precursor protein (APP), and also had the same impact on amyloid proteins in the brains of transgenic mice used as animal models of AD. Importantly 2-PMAP also prevented the cognitive deficits that are normally seen in these mice as they age. The studies also suggest that the compound appears to have a highly selective effect, by interfering with the translation of APP’s gene transcript into the APP protein itself.

 

Click here for the full press release and click here for a story by Fierce Biotech.

 

 

January 16, 2014:  Aria Neurosciences Signs Letter of Intent with Harvard/Massachusetts General Hospital (MGH).  Aria Neurosciences has entered into discussions with Massachusetts General Hospital (MGH) to establish a collaborative research agreement with the laboratory of Dr. Jack Rogers, a leading expert in field of Alzheimer’s disease.  The collaboration would focus on the testing and evaluation of Aria’s lead compounds for Alzheimer’s disease by Dr. Rogers’ laboratory as well as Aria’s evaluation of compounds discovered by Dr. Rogers’ laboratory with an option to potentially license the technology from MGH.

 

 

December 19, 2013:  USPTO Issues Allowance of Aria Neurosciences Patent for Alzheimer’s Disease Compounds.    Aria Neurosciences, an emerging biotechnology company developing disease modifying treatments for patients with Alzheimer’s disease (AD), has been allowed the issuance of Aria’s first patent application surrounding its new class of Amyloid Precursor Protein mRNA modulator compounds in preclinical development.  The patent claims cover the composition of matter and use of these compounds “This is a proud moment for Aria, as these compounds appear to have a novel mechanism of action for Alzheimer ’s disease and have been shown to be effective in lowering amyloid load and preserving memory in preclinical transgenic mice disease models”, stated Aria President and CEO Bijan Almassian, Ph.D.

 

June 1, 2013 -  Aria Neurosciences fills key leadership positions. Mark A. Findeis, Ph.D has joined as a Corporate Research Advisor and Marc Silver has joined as Vice President of Business Operations. Please see more details under Management Bios.

June 18, 2012 - Hamden, CT:  NYU/Aria Neurosciences abstract "An APP Translation Modulator ARN2966 Reduces Aß Deposition and Prevents Memory Deficit in AD Transgenic Mice" has been accepted for a symposium oral presentation at the Alzheimer’s Association International Conference (AAIC) in Vancouver, British Columbia, Canada, July 18, 2012 from 9:10 am to 9:30 am

May 1, 2011 - HAMDEN, CT:  Aria Neurosciences, Inc. signed a license agreement with  NYU School of Medicine for the intellectual property (IP) associated with the pending U.S. provisional patent application, Serial No 61,407,393, owned by both parties. The IP covers the use of Pyridin-2-methylamine derivatives as new therapeutics and/or prophylactic agent for Alzheimer's disease and related disorders.

CONTACT

 

Aria Neurosciences, Inc.

295 Washington Ave, Suite 4N

Hamden, CT 06518

Tel:(203) 815-5782

www.arianeurosciences.com

Alzheimer's Disease

Copyright © 2013 Aria Neurosciences, Inc.

I

I

I